Analysis of Statins Use in a Shanghai Hospital under the Policy of Drug Quantity Purchasing
- VernacularTitle:带量采购政策下他汀类药物在上海某院的应用情况分析
- Author:
Xian ZHANG
1
;
Hongjun CHEN
2
Author Information
1. School of Basic Medical Sciences，Fudan University，Shanghai 200032，China
2. Dept. of Pharmacy，Shanghai Yangpu District Central Hospital （Yangpu Hospital Affiliated to Tongji University），Shanghai 200090，China
- Publication Type:Journal Article
- Keywords:
Drug quantity purchasing;
Third batch of Shanghai drug quantity purchasing;
National“4 + 7”drug quantity
- From:
China Pharmacy
2021;32(2):247-253
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE：To investigate the effects of the third batc h of Shanghai drug quantity purchasing and national “4+7” drug quantity purchasing in a Shanghai hospital and its impact on the use of statins. METHODS ：Consumption amount （tablets） and sum of statins were collected from information system of this hospital before （Feb. 10th-Aug. 31th，2018）and after （Sept. 1th，2018-Mar. 19th，2019）the implementation of the third batch of Shanghai drug quantity purchasing ，after the implementation of national “4+7”drug quantity purchasing （Mar. 20th-Oct. 9th，2019）. The defined drug frequency （DDDs）and average defined daily cost （DDC） of above 3 periods were calculated according to drug defined daily dose （DDD） recommended by New Pharmacology and related drug instructions ，so as to analyzethe influence of the third batch of Shanghaidrug quantity purchasing and national “4+7”drug quantity purchasing on the use of statins in this hospital and predict the market share trend of each specification in this hospital. RESULTS & CONCLUSIONS ：Before the implementation of the third batch of Shanghaidrug quantity purchasing，there were 5 varieties and 8 specifications of statins in this hospital ；after the implementation of quantity purchasing ，it was adjusted to 5 varieties and 9 specifications. The amount of Simvastatin tablets was small in general ，and its consumption sum also continued to decline after the implementation of quantity purchasing. The amount of Rosuvastatin calcium tablets accounted for 49.49％ before the implementation of quantity purchasing ，ranking the first ；after the implementation of 3 batches of Shanghai drug quantity purchasing ， the amount proportion decreased to Δ 基金项目：上海市科学技术委员会科研计划项目（No.19ZR1450- 600） below 30％，and consumption sum proportion decreased from ＊本科 。研究方向 ：医药市场研究与分析 。电话 ：021- 37.82％ to 18.77％；after the implementation of national “4+ 54237308。E-mail：2123398711@qq.com 7”drug quantity purchasing ，the consumption sum proportion # 通信作者 ：副主任药师 ，博士。研究方向 ：临床药学 。电话： continued to decline to 17.38％ .The amount of Atorvastatin 021-65690520。E-mail：Hongjun.chen@tongji.edu.cn calcium tablets increased significantly after the implementation 中国药房 2021年第32卷第2期 China Pharmacy 2021Vol. 32 No. 2 ·247· of the thi rd batch of Shanghaidrug quantity purchasing ，from 41.55％ to 54.09％，and decreased slightly after the implementation of the national “4+7”drug quantity purchasing ，but the amount proportion was still as high as 53.06％，ranking the first ；before and after the implementation of quantity purchasing ，the proportions of its consumption sum were ranked the first ，which remained at about 50％，being 52.87％，61.18％ and 46.50％，respectively. Compared with the amount before the implementation of the third batch of Shanghaidrug quantity purchasing ，the amount of its generic drugs increased by 40.32％，but the consumption sum decreased by 78.18％. Any one type of Pravastatin sodium tablets and Pitavastatin calcium tablets was not selected ；the proportion of them was increased continuously ，but the overall proportion was relatively small. The price of statins decreased significantly after included in quantity purchasinglist. It is expected that the market share of simvastatin in thise hospital will continue to shrink ，and that of atorvastatin may continue to expand. Due to more adverse reactions ，rosuvastatin has limited room to expand ，and pravastatin accounts for a small proportion ，but there is still a demand for patients. Because pitavastatin is a new drug ，its application in this hospital needs more clinical data support.
